I have so much going on right now that even slowing down to try and think of it all, my head is going to melt down. So, I’ll just throw them out there.
1. Because Hannah’s mutation combination has never been seen before, there is no way to determine if she is type 2 or type 3. However, because she does have the mutation of D409H, literature has described this to be associated with cardiac problems so Hannah’s neurologist recommends that she should have a cardiac echo. He also recommends a brain MRI should be done at some point soon as a baseline.
He also suggested to do a special skin biopsy study to try to differentiate between type 2 and 3. This may be the best way. I contacted the geneticist at the National Institute of Health (NIH) he recommended, and we will take it from there.
2. I heard from Dr. Ari Azhir from Neuraltus, the company that put out the press release last week regarding a possible new Gaucher’s drug. Basically, she never did confirm it was for type 2 or type 3, but she did say “We understand that the drugs we are working on are of the greatest importance to you.” So, I’ll just still HOPE that it is for GD2 or GD3. She said she will keep in touch with me on their progress and, when they are ready, we will see if Hannah fits their criteria for a clinical trial.
3. I need $500,000. No, that is not a typo! After the success Chris had with the NPC discovery below, I want to be able to put together a research team instead of just relying on a team that has been put together for multiple issues. We need one team of researchers dedicated to thinking “outside the box” (as they did with NPC) and come up with SOMETHING for GD2 and GD3 either entirely new or to assist those few researchers out there who are actually working on GD2 and GD3.
But for now, I’ll keep working on my $10,000 goal by July 25 ($6600 to go) to help get the “mouse” finished so that researchers can start testing their ideas. At least once we have that mouse that will be a HUGE step forward for GD2 and GD3 research!
Latest Comments